Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 4, 2010, Pages 830-837

  Contoli, Marco ^a   Baraldo, Simonetta ^b   Marku, Brunilda ^a   Casolari, Paolo ^a   Marwick, John A ^a,d   Turato, Graziella ^b   Romagnoli, Micaela ^c   Caramori, Gaetano ^a   Saetta, Marina ^b   Fabbri, Leonardo M ^e   Papi, Alberto ^a  

^a Research Centre on Asthma   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

airway inflammation; Asthma; chronic obstructive pulmonary disease; comorbidities; exacerbations; lung function; natural history

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; NITRIC OXIDE; PREDNISONE; SALBUTAMOL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; EMPHYSEMA; EOSINOPHIL COUNT; EXPIRED AIR; FEMALE; FIXED AIRFLOW OBSTRUCTION; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LYMPHOCYTE COUNT; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS;

AGED; AIRWAY OBSTRUCTION; ASTHMA; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 77950297480     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.01.003     Document Type: Article

References (45)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report. 2002 (2008), National Institutes of Health, Bethesda NIH publication no. 02-3659
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). National Institute of Health; National Heart Lung, and Blood Institute. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop report (2008), National Institutes of Health, Bethesda NIH publication no. 2701A 2001
3. Holgate S.T. Pathogenesis of asthma. Clin Exp Allergy 38 (2008) 872-897
4. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med 343 (2000) 269-280
5. Saetta M., Turato G., Maestrelli P., Mapp C.E., and Fabbri L.M. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163 (2001) 1304-1309
6. ten Brinke A. Risk factors associated with irreversible airflow limitation in asthma. Curr Opin Allergy Clin Immunol 8 (2008) 63-69
7. Mannino D.M., Gagnon R.C., Petty T.L., and Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 160 (2000) 1683-1689
8. Ulrik C.S., and Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 14 (1999) 892-896
9. ten Brinke A., Zwinderman A.H., Sterk P.J., Rabe K.F., and Bel E.H. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 164 (2001) 744-748
10. Lange P., Parner J., Vestbo J., Schnohr P., and Jensen G.A. 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339 (1998) 1194-1200
11. Fabbri L.M., Romagnoli M., Corbetta L., Casoni G., Busljetic K., Turato G., et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167 (2003) 418-424
12. Gibson P.G., and Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it?. Thorax 64 (2009) 728-735
13. Papi A., Romagnoli M., Baraldo S., Braccioni F., Guzzinati I., Saetta M., et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162 (2000) 1773-1777
14. Efthimiadis A., Spanevello A., Hamid Q., Kelly M.M., Linden M., Louis R., et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl suppl (2002) 3 7:19s-23
15. Crapo R.O., Casaburi R., Coates A.L., Enright P.L., Hankinson J.L., Irvin C.G., et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 161 (2000) 309-329
16. European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 22 (2003) 470-477
17. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
18. Bousquet J., Boulet L.P., Peters M.J., Magnussen H., Quiralte J., Martinez-Aguilar N.E., et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 101 (2007) 2437-2446
19. Busse W.W., Pedersen S., Pauwels R.A., Tan W.C., Chen Y.Z., Lamm C.J., et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 121 (2008) 1167-1174
20. Rabe K.F., Atienza T., Magyar P., Larsson P., Jorup C., and Lalloo U.G. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368 (2006) 744-753
21. Calverley P.M., Rabe K.F., Goehring U.M., Kristiansen S., Fabbri L.M., and Martinez F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374 (2009) 685-694
22. Wedzicha J.A., Calverley P.M., Seemungal T.A., Hagan G., Ansari Z., and Stockley R.A. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177 (2008) 19-26
23. Welte T., Miravitlles M., Hernandez P., Eriksson G., Peterson S., Polanowski T., et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180 (2009) 741-750
24. Miller M.R., Crapo R., Hankinson J., Brusasco V., Burgos F., Casaburi R., et al. General considerations for lung function testing. Eur Respir J 26 (2005) 153-161
25. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 26 (2005) 319-338
26. Marti S., Munoz X., Rios J., Morell F., and Ferrer J. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J 27 (2006) 689-696
27. Crisafulli E., Costi S., Luppi F., Cirelli G., Cilione C., Coletti O., et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 63 (2008) 487-492
28. Paganin F., Séneterre E., Chanez P., Daurés J.P., Bruel J.M., Michel F.B., et al. Computed tomography of the lungs in asthma: influence of disease severity and aetiology. Am J Respir Crit Care Med 153 (1996) 110-114
29. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
30. James A.L., Palmer L.J., Kicic E., Maxwell P.S., Lagan S.E., Ryan G.F., et al. Decline in lung function in the Besselton health study. The effects of asthma and cigarette smoking. Am J Respir Crit Care Med 171 (2005) 109-114
31. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
32. Celli B.R., Thomas N.E., Anderson J.A., Ferguson G.T., Jenkins C.R., Jones P.W., et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178 (2008) 332-338
33. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 1543-1554
34. Burrows B., Bloom J.W., Traver G.A., and Cline M.G. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 317 (1987) 1309-1314
35. Rasmussen F., Taylor D.R., Flannery E.M., Cowan J.O., Greene J.M., Herbison G.P., et al. Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med 165 (2002) 1480-1488
36. Di Stefano A., Capelli A., Lusuardi M., Balbo P., Vecchio C., Maestrelli P., et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 158 (1998) 1277-1285
37. O'Donnell R.A., Peebles C., Ward J.A., Daraker A., Angco G., Broberg P., et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 59 (2004) 837-842
38. Donaldson G.C., Seemungal T.A., Bhowmik A., and Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 (2002) 847-852
39. van Veen I.H., Ten Brinke A., Sterk P.J., Sont J.K., Gauw S.A., Rabe K.F., et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 32 (2008) 344-349
40. Bai T.R., Vonk J.M., Postma D.S., and Boezen H.M. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 30 (2007) 452-456
41. O'Byrne P.M., Pedersen S., Lamm C.J., Tan W.C., and Busse W.W. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 179 (2009) 19-24
42. van Manen J.G., Bindels P.J., Cj Ij van der Zee J.S., Bottema B.J., and Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 54 (2001) 287-293
43. Mapel D.W., Hurley J.S., Frost F.J., Petersen H.V., Picchi M.A., and Coultas D.B. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 160 (2000) 2653-2658
44. Fabbri L.M., and Rabe K.F. From COPD to chronic systemic inflammatory syndrome?. Lancet 370 (2007) 797-799
45. Mucha L., Stephenson J., Morandi N., and Dirani R. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. Gend Med 3 (2006) 279-291